Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin and Dapagliflozin Dual Add-on in Type 2 Diabetes
NCT04255238Phase 3Unknown
- Sponsor
- LG Chem
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Gemigliptin + Dapagliflozin, Gemigliptin Control and Dapagliflozin Control (3 arms). Primary endpoint: Change from baseline HbA1c at Week 24. Status: unknown.
02
Drugs
gemigliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04255238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255238.